ADMA Biologics, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD 158.29 M

ADMA Biologics, Inc. EBITDA is USD 158.29 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 471.53% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • ADMA Biologics, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 27.70 M, a -252.82% change year over year.
  • ADMA Biologics, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -18.12 M, a -69.37% change year over year.
  • ADMA Biologics, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -59.17 M, a 1.95% change year over year.
  • ADMA Biologics, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -58.04 M, a 41.40% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)